InvestorsHub Logo
Followers 2
Posts 90
Boards Moderated 0
Alias Born 11/12/2020

Re: Gustyhu post# 27417

Saturday, 04/03/2021 1:23:39 AM

Saturday, April 03, 2021 1:23:39 AM

Post# of 42553
Not sure where they failed. Their Press Release stated:

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen of approximately $92.5 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about April 5, 2021. Humanigen also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions.

What was wrong with this? Or was the failure in one of the 8K prospectus filings?